Indoco Remedies Valuation
Is 532612 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 532612 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 532612 (₹324.85) is trading below our estimate of fair value (₹567.51)
Significantly Below Fair Value: 532612 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 532612?
Key metric: As 532612 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 532612's PE Ratio? | |
|---|---|
| PE Ratio | 93.4x |
| Earnings | ₹320.60m |
| Market Cap | ₹29.94b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.1x |
| Enterprise Value/EBITDA | 22.6x |
| PEG Ratio | 1.3x |
Price to Earnings Ratio vs Peers
How does 532612's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 50.8x | ||
530199 Themis Medicare | 50.6x | n/a | ₹26.8b |
RPGLIFE RPG Life Sciences | 51.9x | n/a | ₹36.7b |
506879 Gujarat Themis Biosyn | 67.9x | n/a | ₹35.8b |
500288 Morepen Laboratories | 32.9x | n/a | ₹43.3b |
532612 Indoco Remedies | 93.4x | 72.2% | ₹29.9b |
Price-To-Earnings vs Peers: 532612 is expensive based on its Price-To-Earnings Ratio (93.4x) compared to the peer average (50.8x).
Price to Earnings Ratio vs Industry
How does 532612's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
INDSWFTLAB Ind-Swift Laboratories | 1.5x | n/a | US$66.09m |
524652 Ind-Swift | 2x | n/a | US$13.18m |
| 2 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 532612 is expensive based on its Price-To-Earnings Ratio (93.4x) compared to the Indian Pharmaceuticals industry average (33.1x).
Price to Earnings Ratio vs Fair Ratio
What is 532612's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 93.4x |
| Fair PE Ratio | 74.7x |
Price-To-Earnings vs Fair Ratio: 532612 is expensive based on its Price-To-Earnings Ratio (93.4x) compared to the estimated Fair Price-To-Earnings Ratio (74.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₹324.85 | ₹312.40 -3.8% | 5.7% | ₹338.00 | ₹290.00 | n/a | 5 |
| Nov ’25 | ₹314.70 | ₹312.40 -0.7% | 5.7% | ₹338.00 | ₹290.00 | n/a | 5 |
| Oct ’25 | ₹348.55 | ₹346.00 -0.7% | 8.4% | ₹400.00 | ₹320.00 | n/a | 5 |
| Sep ’25 | ₹361.20 | ₹346.00 -4.2% | 8.4% | ₹400.00 | ₹320.00 | n/a | 5 |
| Aug ’25 | ₹330.15 | ₹346.00 +4.8% | 8.4% | ₹400.00 | ₹320.00 | n/a | 5 |
| Jul ’25 | ₹331.00 | ₹356.40 +7.7% | 11.9% | ₹438.00 | ₹318.00 | n/a | 5 |
| Jun ’25 | ₹299.75 | ₹356.40 +18.9% | 11.9% | ₹438.00 | ₹318.00 | n/a | 5 |
| May ’25 | ₹327.00 | ₹395.20 +20.9% | 7.7% | ₹438.00 | ₹358.00 | n/a | 5 |
| Apr ’25 | ₹339.55 | ₹395.20 +16.4% | 7.7% | ₹438.00 | ₹358.00 | n/a | 5 |
| Mar ’25 | ₹345.85 | ₹395.20 +14.3% | 7.7% | ₹438.00 | ₹358.00 | n/a | 5 |
| Feb ’25 | ₹369.15 | ₹392.67 +6.4% | 7.2% | ₹438.00 | ₹358.00 | n/a | 6 |
| Jan ’25 | ₹390.25 | ₹390.50 +0.06% | 4.2% | ₹425.00 | ₹375.00 | n/a | 6 |
| Dec ’24 | ₹371.40 | ₹392.57 +5.7% | 4.1% | ₹425.00 | ₹375.00 | n/a | 7 |
| Nov ’24 | ₹318.15 | ₹392.57 +23.4% | 4.1% | ₹425.00 | ₹375.00 | ₹314.70 | 7 |
| Oct ’24 | ₹338.70 | ₹381.00 +12.5% | 3.4% | ₹405.00 | ₹361.00 | ₹348.55 | 6 |
| Sep ’24 | ₹311.90 | ₹381.00 +22.2% | 3.4% | ₹405.00 | ₹361.00 | ₹361.20 | 6 |
| Aug ’24 | ₹314.60 | ₹381.00 +21.1% | 3.4% | ₹405.00 | ₹361.00 | ₹330.15 | 6 |
| Jul ’24 | ₹327.05 | ₹409.00 +25.1% | 2.9% | ₹430.00 | ₹396.00 | ₹331.00 | 6 |
| Jun ’24 | ₹344.25 | ₹422.00 +22.6% | 6.0% | ₹474.00 | ₹400.00 | ₹299.75 | 6 |
| May ’24 | ₹323.30 | ₹453.17 +40.2% | 6.1% | ₹513.00 | ₹430.00 | ₹327.00 | 6 |
| Apr ’24 | ₹325.55 | ₹453.17 +39.2% | 6.1% | ₹513.00 | ₹430.00 | ₹339.55 | 6 |
| Mar ’24 | ₹354.45 | ₹453.17 +27.9% | 6.1% | ₹513.00 | ₹430.00 | ₹345.85 | 6 |
| Feb ’24 | ₹324.25 | ₹454.83 +40.3% | 5.9% | ₹513.00 | ₹430.00 | ₹369.15 | 6 |
| Jan ’24 | ₹406.85 | ₹486.00 +19.5% | 10.5% | ₹563.00 | ₹430.00 | ₹390.25 | 6 |
| Dec ’23 | ₹393.80 | ₹486.00 +23.4% | 10.5% | ₹563.00 | ₹430.00 | ₹371.40 | 6 |
| Nov ’23 | ₹354.20 | ₹480.33 +35.6% | 10.6% | ₹550.00 | ₹410.00 | ₹318.15 | 6 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
Vivimed Labs
₹410.4m
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.
VIVIMEDLAB
₹4.95
7D
0%
1Y
-45.9%
Novartis India
₹26.9b
Operates as a healthcare company in India.
500672
₹1,090.30
7D
6.3%
1Y
54.5%
Colinz Laboratories
₹142.4m
Manufactures, markets, and trades in pharmaceutical formulations in India.
531210
₹56.52
7D
2.7%
1Y
34.5%